Abstract | INTRODUCTION: METHODS: We conducted a meta-analysis of RCTs of echinocandins and non- echinocandins for adult invasive candidiasis. The MEDLINE, Web of Sciences, Cochrane Register of Controlled Trials, and ClinicalTrials.gov databases before June 2019 were used. The risk ratio (RR) and 95% confidence interval (95% CI) were calculated using the Mantel-Haenszel method random-effects model. RESULTS: We identified 14,846 articles and screened, and five studies were included meta-analysis. The treatment success ratio for echinocandins was significantly higher than that for non- echinocandins (RR = 1.14, 95% CI 1.06-1.22, p = 0.0003). In regard to adverse events, there was no significant difference between the two treatment groups. A subgroup analysis showed that the treatment success ratio for echinocandins was significantly higher than that for azoles (RR = 1.20, 1.08-1.34, p = 0.001), whereas no significant differences were observed between echinocandins and polyenes. In safety analysis, the incidence ratio of electrolyte disorder (RR = 0.50, 0.33-0.76, p = 0.001), renal disorder (RR = 0.19, 0.09-0.40, p < 0.0001), and fever (RR = 0.46, 0.23-0.93, p = 0.03) were significantly lower in patients receiving echinocandins than in those receiving polyenes. CONCLUSIONS:
|
Authors | Sho Tashiro, Sumika Osa, Yuki Igarashi, Yuki Watabe, Xiaoxi Liu, Yuki Enoki, Kazuaki Taguchi, Toshihiko Mayumi, Yoshitsugu Miyazaki, Yoshio Takesue, Kazuaki Matsumoto |
Journal | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
(J Infect Chemother)
Vol. 26
Issue 11
Pg. 1164-1176
(Nov 2020)
ISSN: 1437-7780 [Electronic] Netherlands |
PMID | 32620421
(Publication Type: Journal Article, Meta-Analysis)
|
Copyright | Copyright © 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. |
Chemical References |
- Antifungal Agents
- Azoles
- Echinocandins
|
Topics |
- Adult
- Antifungal Agents
(adverse effects)
- Azoles
- Candidiasis, Invasive
(drug therapy)
- Echinocandins
(adverse effects)
- Humans
- Randomized Controlled Trials as Topic
|